|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:drug
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:ATCCode
|
gptkb:N05AX12
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
disintegrating tablet
injectable suspension
|
|
gptkbp:brand
|
gptkb:Abilify
|
|
gptkbp:CASNumber
|
129722-12-9
|
|
gptkbp:chemicalFormula
|
C23H27Cl2N3O2
|
|
gptkbp:contraindication
|
hypersensitivity to aripiprazole
|
|
gptkbp:developedBy
|
gptkb:Otsuka_Pharmaceutical
|
|
gptkbp:drugClass
|
gptkb:antipsychotic_medication
|
|
gptkbp:eliminationHalfLife
|
75 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1988
|
|
gptkbp:KEGGID
|
D07441
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist at serotonin 5-HT2A receptor
partial agonist at dopamine D2 receptor
partial agonist at serotonin 5-HT1A receptor
|
|
gptkbp:MedlinePlusID
|
a603012
|
|
gptkbp:metabolism
|
liver (CYP2D6, CYP3A4)
|
|
gptkbp:molecularWeight
|
448.38 g/mol
|
|
gptkbp:patentExpired
|
2014 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
60795
CHEMBL111
DB01238
|
|
gptkbp:riskFactor
|
suicidal thoughts
extrapyramidal symptoms
neuroleptic malignant syndrome
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
weight gain
restlessness
insomnia
tardive dyskinesia
akathisia
|
|
gptkbp:UNII
|
82VFR53I78
|
|
gptkbp:usedFor
|
bipolar disorder
schizophrenia
Tourette syndrome
irritability associated with autism
major depressive disorder (adjunct)
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Abilify
gptkb:CYP3A4
gptkb:N05AX
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aripiprazole
|